TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
KARD

Kardigan, Inc.

Healthcare · Biotechnology

14.10$ -9.9% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns Kardigan, Inc. (KARD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 55.4% of the shares are freely tradable; institutional investors hold 41.4%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 41.4%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 35.0%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 55.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 7.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 94Mio.

Largest Shareholders

Institutions

Institutions KARD
Name Stake (%) Shares Change (%) Date
SCHF (GPE), LLC 18.09 16,917,034 +0.0 06/30/2026
FMR Inc 9.53 8,909,066 +0.0 06/30/2026
Perceptive Advisors LLC 8.77 8,200,662 +0.0 06/30/2026
T. Rowe Price Investment Management,Inc. 4.50 4,207,130 +0.0 06/30/2026
Capital Research Global Investors 3.85 3,598,942 +0.0 06/30/2026
JPMorgan Chase & Co 1.92 1,790,734 +0.0 06/30/2026
AllianceBernstein L.P. 1.64 1,534,837 +0.0 06/30/2026
Liberty Mutual Group Asset Management Inc. 1.28 1,196,411 +0.0 06/30/2026

Funds

Funds KARD
Name Stake (%) Shares Change (%) Date
American Funds SMALLCAP World A 3.77 3,525,648 +0.6 09/30/2026
Fidelity Contrafund 1.59 1,486,443 +18.9 09/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?